Mindray(SZ:300760) 仪器信息网·2025-10-31 09:39Core Viewpoint - The article discusses the financial performance and strategic initiatives of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. for the third quarter of 2025, highlighting both challenges and growth opportunities in various business segments. Financial Data Summary - The company's operating revenue for the third quarter of 2025 was CNY 9,090,902,689, representing a year-on-year increase of 1.53%. However, the total revenue for the first three quarters decreased by 12.38% to CNY 25,833,906,543 [2][13]. - The net profit attributable to shareholders for the third quarter was CNY 2,501,277,420, down 18.69% year-on-year, while the net profit for the first three quarters fell by 28.83% to CNY 7,570,044,518 [2][13]. - The basic earnings per share for the third quarter was CNY 2.0641, a decrease of 18.62% compared to the previous year [2][13]. - The company's total assets increased by 4.63% to CNY 59,265,123,962 compared to the end of the previous year [2][13]. Business Segment Performance - The international business segment saw a year-on-year growth of 11.93% in the third quarter, with significant contributions from the European market, which grew over 20% [13][14]. - The Life Information and Support segment generated CNY 29.52 billion in revenue for the third quarter, a growth of 2.60%, with minimally invasive surgery business growing over 25% [14][15]. - The Medical Imaging segment's revenue was CNY 16.89 billion, remaining stable year-on-year, while the In Vitro Diagnostics segment saw a decline of 2.81% to CNY 36.34 billion [14][15]. Research and Development - The company maintained a high level of R&D investment, amounting to CNY 268,642,960, which is 10.40% of its operating revenue for the first three quarters of 2025 [17]. - New product launches included high-sensitivity cardiac troponin T assay kits and various imaging systems, enhancing the product portfolio [17][18]. Sustainability Initiatives - Mindray has been active in promoting public emergency awareness, training 40,000 individuals in first aid, and successfully aiding 415 cardiac arrest patients with AEDs [19][20]. - The company partnered with Smile Train to provide free medical assistance for cleft lip and palate patients, conducting surgeries for 213 individuals [19][20]. Shareholder Returns - The company has consistently prioritized shareholder returns, distributing cash dividends totaling CNY 15.88 billion in 2025, with cumulative dividends since its IPO reaching approximately CNY 357 billion [22].